The ‘Global Sjogren’s Syndrome Treatment Market Share, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global Sjogren’s syndrome treatment market, assessing the market on the basis of its segments like drug class, indication type, therapeutic agents, route of administration, distribution channel, and major regions.
The report also provides a detailed insight of the market on the basis of patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnership and collaborations analysis.
The key highlights of the report include:
Market Overview (2016-2031)
- Historical Market Size: USD 311.7 Million
- Forecast CAGR (2023-2031):0%
- Forecast Market Size: USD 427.3 Million
Growing awareness of autoimmune diseases and advancements in diagnostics are expected to drive the growth of the global Sjogren’s syndrome treatment market. Increasing investments in research and development, along with a rising number of drugs in clinical trials by leading pharmaceutical companies for Sjogren’s syndrome, are expected to offer lucrative growth opportunities to the market. However, a lack of specific treatment options and challenges in diagnosing the disease may pose challenges for the Sjogren’s syndrome treatment market.
Advancements in diagnostic techniques and a better understanding of the disease’s pathophysiology have led to improved management of Sjogren’s syndrome. The development of novel targeted therapies and personalized medicine approaches for the treatment of the disease are expected to have a positive impact on the global Sjogren’s syndrome treatment market growth. Over the forecast period, the anticipated increase in research and development activities for Sjogren’s syndrome treatment and the growing demand for novel therapies are expected to drive the market growth. These developments, coupled with the strengthening healthcare infrastructure, are likely to contribute to the market growth.
Industry Definition and Major Segments
Sjogren’s syndrome is an autoimmune disorder characterized by the malfunctioning of the immune system, leading to the attack of healthy tissues, particularly affecting moisture-producing glands, such as salivary and lacrimal glands. The disease primarily causes dryness in the mouth and eyes, and it can also affect other organs and systems of the body. Treatment options for Sjogren’s syndrome include symptomatic management, immunosuppressive agents, and targeted therapies.
Based on drug type, the market is segmented into:
- Cholinergic Agonists
- Off-Label Drugs
Based on indication type, the market is segmented into:
- Primary Sjogren’s Syndrome
- Secondary Sjogren’s Syndrome
Based on therapeutic agents, the market is segmented into:
- Targeted Drugs
- Pain Relievers
- Symptom Modulators
Based on the route of administration, the market is classified into:
Based on distribution channel, the market is bifurcated into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on region, the market is segregated into:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
The key trends in the global Sjogren’s syndrome treatment market include the growing development and research in the healthcare sector, aimed towards developing novel drug combinations and targeted therapies to combat the disease. A better understanding of the underlying immunological mechanisms has led to the identification of potential therapeutic targets for Sjogren’s syndrome, which is expected to drive market growth.
Significant advancements in the field of immunology and molecular biology have resulted in a better understanding of the pathophysiology of Sjogren’s syndrome, leading to the development of novel targeted therapies. Additionally, the increased focus on personalized medicine approaches for the treatment of autoimmune diseases is expected to contribute to global Sjogren’s syndrome treatment market growth.
Increased clinical trials involving immunotherapy drugs, targeted therapy, and novel immunosuppressive agents are projected to boost market growth. The development of biomarkers for early diagnosis and monitoring disease activity is also expected to impact the growth of the market positively. The incorporation of multidisciplinary management strategies, including collaborations between rheumatologists, ophthalmologists, and dentists, is expected to enhance the quality of care for patients with Sjogren’s syndrome and boost the growth of the market.
Sjogren’s Syndrome Treatment Market
The major players in the global Sjogren’s syndrome treatment market report include Denali Therapeutics, Clovis Oncology, Horizon Therapeutics plc, Sangamo Therapeutics, AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments, and mergers and acquisitions, among other latest developments of these market players.
The report studies the latest updates in the market, along with their impact across the market. It also analyzes the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.